(018) Assessment of platinum and taxane agent-related infusion reactions before and after vaccination with Coronavirus Disease 2019 (COVID-19) mRNA vaccine

Poster Abstract: Background/Rationale: Platinum and taxane agents are utilized in first-line treatment regimens for various solid organ tumors including ovarian, lung, and head and neck cancers. These agents have been associated with significant infusion-related hypersensitivity reactions that present a barrier to continued treatment with preferred regimens. Infusion reactions may lead to an increase in infusion chair time, hospital admission, and increased healthcare costs. Historically, infusion reaction rates of 8-16 % for carboplatin, 5-20% for cisplatin, 7-24% for oxaliplatin, 4-10% for paclitaxel, and 5% for docetaxel have been reported. Providers at the Medical University of South Carolina Hollings Cancer Center noticed an increase in chemotherapy infusion reactions in the post-COVID-19 vaccination era. This study aims to assess the rate of infusion reactions related to platinum or taxane agents after vaccination with COVID-19 mRNA vaccine to better identify those at risk.

Objective: To assess the rate of infusion reactions during treatment with platinum or taxane agents before and after immunization with COVID-19 mRNA vaccine.

Methods: This is a single center, retrospective, observational study performed at the Medical University of South Carolina Hollings Cancer Center. Data will be collected by electronic and manual chart review for all patients 18 years or older who experienced an infusion reaction during treatment with a platinum or taxane agent between January 1st, 2021 and January 1st, 2023. Infusion reactions will be identified by any of the following: an allergy to a platinum or taxane agent listed in the patient’s EPIC chart, an order placed for oxaliplatin with an infusion time > 120 minutes, and/or an order placed for a platinum or taxane desensitization treatment plan. Patients who are pregnant will be excluded. Data to be collected includes: age, gender, history of vaccination with COVID-19 mRNA vaccine, prior allergies, cancer diagnosis, and cancer stage. Data will be de-identified and patient information will remain confidential. The primary outcome will be the proportion of patients that received a COVID-19 mRNA vaccine and experienced an infusion reaction during treatment with a platinum or taxane agent. This number will be compared to historical controls to identify if an increased reaction rate has been observed due to COVID-19 mRNA vaccination at this institution. Additional patient, pathologic, and treatment specific factors will be assessed to identify potential risk factors for infusion reactions during treatment with platinum or taxane agents. Descriptive statistics will be utilized to assess outcomes.

Results: results pending

Discussion/

Conclusion: results pending

References (must also be included in final poster): Tsao, L. R., Young, F. D., Otani, I. M., & Castells, M. C. Hypersensitivity Reactions to Platinum Agents and Taxanes. Clinical reviews in allergy & immunology. 2022; 62(3): 432–448.

Weiss RB, et al. Hypersensitivity Reactions to the Taxanes Paclitaxel and Docetaxel. Journal of Clinical Oncology. 1990; 8(7):1263-8.